

ELMMB Formulary Update

November 2016

'Follow' us on or 'Like' us on

Email interface@eastlancashireccg.nhs.uk
with any comments or questions

BLACK Traffic Light - not recommended for prescribing in primary or secondary care

- **Colesevelam** (Cholestagel) – not recommended as combination or monotherapy for familial hypercholesterolaemia.
- **E- cigarettes** – not recommended for prescribing in ELHE
- **Necitumumab** (Portrazza®) – untreated advanced or metastatic squamous non-small-cell lung cancer [NICE TA411](#)
- **Tapentadol MR** (Palexia) – not recommended as a treatment option for intractable neuropathic pain in non-palliative care patients or for non-specific pain. (use in palliative care still under review).

RED Traffic Light - primary care prescribers should not be asked to prescribe

- **Secukinumab** (Cosentyx®) – active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors [NICE TA407](#)
- **Crizotinib** (Xalkori®) – untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer [NICE TA406](#)
- **Radium 223 dichloride** (Xofigo®) – hormone relapsed prostate cancer with bone metastases [NICE TA412](#)
- **Metolazone** – unlicensed preparation to remain RED traffic light. Supply arrangements to be made in secondary care.
- **Aflibercept** (Eylea®) – visual impairment caused by macular oedema after branch retinal vein occlusion [NICE TA409](#)
- **Talimogene laherparepvec** (Imlygic®) – unresectable metastatic melanoma in adults when systemically administered immunotherapies are not suitable [NICE TA410](#)
- **Pegaspargase** (Ocaspar®) – acute lymphoblastic leukaemia [NICE TA408](#)
- **Sodium Benzoate** – metabolic disorders – RED for all new patients, existing patients to be reviewed.

AMBER Traffic Light - initiated by specialists but may then be passed to primary care for prescribing

- **Degarelix** (Firmagon®) – advanced hormone-dependent prostate cancer: [NICE TA404](#)

GREEN Traffic Light - may be prescribed by all prescribers within local or national recommendations

- **NOACs** – changed from AMBER to reflect use of NOACs.

Guidelines

- **Primary Care Antimicrobial Guidelines** – UTI and 1st line acne treatments updated.
- **LMWH Summary Prescribing Guideline** – accepted for information only, continue to use [ELHE Best Practice Guidance](#)
- **Psoriasis Biologics pathway**
- **Quetiapine MR to Quetiapine switching guidance for health professionals** – (LCFT)
- **Gastroenterology Biologics Pathway – Crohn's disease**

Other

- [Medicines Management Board Minutes October 2016](#)
- [NICE Bites October 2016](#)
- [Drug Safety Update October 2016](#)
- [Hot Topic – Advice to Care Homes re urine testing of the elderly for UTI](#)
- [Tapentadol MR Position Statement](#)
- [E- cigarettes position statement](#)